ArticleOncogene2026
CRTAC1 inhibits progression of lung adenocarcinoma by suppressing integrin/FAK signaling.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in diagnostics and treatment, lung adenocarcinoma (LUAD) remains one of the leading causes of cancer-related morbidity and mortality worldwide. Identifying novel molecular mechanisms that regulate the progression of LUAD is crucial for improving therapeutic outcomes. Our study reveals that CRTAC1, a natural tumor suppressor, can block the integrin pathway and inhibit the growth and metastasis of LUAD cells. Specifically, our study reveals that CRTAC1 is downregulated significantly in LUAD tissues and that its expression correlates positively with patient survival. Functionally, CRTAC1 inhibits the proliferation, migration, and invasion of LUAD cells both in vitro and in vivo by suppressing integrin/FAK signaling. These findings highlight CRTAC1 as a potential therapeutic target for LUAD, offering new avenues for treatment strategies aimed at reducing tumor progression.
Indexed as
Identifiers
41708954What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.